Logo image of OGI.CA

ORGANIGRAM GLOBAL INC (OGI.CA) Stock Fundamental Analysis

TSX:OGI - Toronto Stock Exchange - CA68617J1003 - Common Stock - Currency: CAD

1.99  +0.03 (+1.53%)

Fundamental Rating

4

Taking everything into account, OGI scores 4 out of 10 in our fundamental rating. OGI was compared to 35 industry peers in the Pharmaceuticals industry. While OGI seems to be doing ok healthwise, there are quite some concerns on its profitability. OGI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

OGI had positive earnings in the past year.
In the past year OGI has reported a negative cash flow from operations.
OGI had negative earnings in each of the past 5 years.
OGI had negative operating cash flow in 4 of the past 5 years.
OGI.CA Yearly Net Income VS EBIT VS OCF VS FCFOGI.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

OGI has a Return On Assets of 3.14%. This is amongst the best in the industry. OGI outperforms 85.71% of its industry peers.
OGI has a Return On Equity of 4.32%. This is amongst the best in the industry. OGI outperforms 85.71% of its industry peers.
Industry RankSector Rank
ROA 3.14%
ROE 4.32%
ROIC N/A
ROA(3y)-32.3%
ROA(5y)-30.36%
ROE(3y)-36.4%
ROE(5y)-36.38%
ROIC(3y)N/A
ROIC(5y)N/A
OGI.CA Yearly ROA, ROE, ROICOGI.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

With an excellent Profit Margin value of 8.70%, OGI belongs to the best of the industry, outperforming 85.71% of the companies in the same industry.
The Operating Margin and Gross Margin are not available for OGI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 8.7%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OGI.CA Yearly Profit, Operating, Gross MarginsOGI.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

4

2. Health

2.1 Basic Checks

OGI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OGI has more shares outstanding
Compared to 5 years ago, OGI has more shares outstanding
OGI has a worse debt/assets ratio than last year.
OGI.CA Yearly Shares OutstandingOGI.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
OGI.CA Yearly Total Debt VS Total AssetsOGI.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -0.22, we must say that OGI is in the distress zone and has some risk of bankruptcy.
OGI's Altman-Z score of -0.22 is in line compared to the rest of the industry. OGI outperforms 60.00% of its industry peers.
A Debt/Equity ratio of 0.11 indicates that OGI is not too dependend on debt financing.
OGI has a Debt to Equity ratio of 0.11. This is in the better half of the industry: OGI outperforms 65.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -0.22
ROIC/WACCN/A
WACC8.62%
OGI.CA Yearly LT Debt VS Equity VS FCFOGI.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 3.42 indicates that OGI has no problem at all paying its short term obligations.
OGI has a Current ratio of 3.42. This is amongst the best in the industry. OGI outperforms 85.71% of its industry peers.
A Quick Ratio of 1.90 indicates that OGI should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.90, OGI is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.42
Quick Ratio 1.9
OGI.CA Yearly Current Assets VS Current LiabilitesOGI.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

6

3. Growth

3.1 Past

OGI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 101.81%, which is quite impressive.
Looking at the last year, OGI shows a very strong growth in Revenue. The Revenue has grown by 26.93%.
OGI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.73% yearly.
EPS 1Y (TTM)101.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%226.92%
Revenue 1Y (TTM)26.93%
Revenue growth 3Y26.37%
Revenue growth 5Y14.73%
Sales Q2Q%74.34%

3.2 Future

Based on estimates for the next years, OGI will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.09% on average per year.
Based on estimates for the next years, OGI will show a quite strong growth in Revenue. The Revenue will grow by 18.97% on average per year.
EPS Next Y49.21%
EPS Next 2Y38.52%
EPS Next 3Y29.86%
EPS Next 5Y19.09%
Revenue Next Year48.22%
Revenue Next 2Y31.13%
Revenue Next 3Y26.16%
Revenue Next 5Y18.97%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
OGI.CA Yearly Revenue VS EstimatesOGI.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
OGI.CA Yearly EPS VS EstimatesOGI.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -0.5 -1 -1.5 -2 -2.5

2

4. Valuation

4.1 Price/Earnings Ratio

OGI is valuated quite expensively with a Price/Earnings ratio of 33.17.
Based on the Price/Earnings ratio, OGI is valued a bit cheaper than 77.14% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.29. OGI is valued slightly more expensive when compared to this.
OGI is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 33.17
Fwd PE N/A
OGI.CA Price Earnings VS Forward Price EarningsOGI.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OGI.CA Per share dataOGI.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

OGI's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as OGI's earnings are expected to grow with 29.86% in the coming years.
PEG (NY)0.67
PEG (5Y)N/A
EPS Next 2Y38.52%
EPS Next 3Y29.86%

0

5. Dividend

5.1 Amount

OGI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ORGANIGRAM GLOBAL INC

TSX:OGI (7/16/2025, 7:00:00 PM)

1.99

+0.03 (+1.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)08-11 2025-08-11
Inst Owners5.59%
Inst Owner ChangeN/A
Ins Owners2.47%
Ins Owner ChangeN/A
Market Cap266.42M
Analysts77.78
Price Target2.84 (42.71%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)258.42%
Min EPS beat(2)-400%
Max EPS beat(2)916.83%
EPS beat(4)2
Avg EPS beat(4)131.47%
Min EPS beat(4)-400%
Max EPS beat(4)916.83%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-3.11%
Min Revenue beat(2)-12.23%
Max Revenue beat(2)6%
Revenue beat(4)3
Avg Revenue beat(4)0.09%
Min Revenue beat(4)-12.23%
Max Revenue beat(4)6%
Revenue beat(8)4
Avg Revenue beat(8)-1.86%
Revenue beat(12)6
Avg Revenue beat(12)-0.65%
Revenue beat(16)9
Avg Revenue beat(16)1.46%
PT rev (1m)0%
PT rev (3m)-1.77%
EPS NQ rev (1m)51.61%
EPS NQ rev (3m)51.61%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0.23%
Revenue NQ rev (3m)4.19%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.13%
Valuation
Industry RankSector Rank
PE 33.17
Fwd PE N/A
P/S 1.37
P/FCF N/A
P/OCF N/A
P/B 0.68
P/tB 0.93
EV/EBITDA N/A
EPS(TTM)0.06
EY3.02%
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS1.45
BVpS2.92
TBVpS2.13
PEG (NY)0.67
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 3.14%
ROE 4.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 8.7%
GM N/A
FCFM N/A
ROA(3y)-32.3%
ROA(5y)-30.36%
ROE(3y)-36.4%
ROE(5y)-36.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.7%
Cap/Sales 5.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.42
Quick Ratio 1.9
Altman-Z -0.22
F-Score3
WACC8.62%
ROIC/WACCN/A
Cap/Depr(3y)118.74%
Cap/Depr(5y)166.77%
Cap/Sales(3y)18.54%
Cap/Sales(5y)32.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)101.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%226.92%
EPS Next Y49.21%
EPS Next 2Y38.52%
EPS Next 3Y29.86%
EPS Next 5Y19.09%
Revenue 1Y (TTM)26.93%
Revenue growth 3Y26.37%
Revenue growth 5Y14.73%
Sales Q2Q%74.34%
Revenue Next Year48.22%
Revenue Next 2Y31.13%
Revenue Next 3Y26.16%
Revenue Next 5Y18.97%
EBIT growth 1Y8.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year134.97%
EBIT Next 3Y49.25%
EBIT Next 5Y29.71%
FCF growth 1Y-7.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-100.66%
OCF growth 3YN/A
OCF growth 5YN/A